نتایج جستجو برای: sofosbuvir

تعداد نتایج: 1451  

Journal: :Gastroenterology 2015
Michael P Curry Xavier Forns Raymond T Chung Norah A Terrault Robert Brown Jonathan M Fenkel Fredric Gordon Jacqueline O'Leary Alexander Kuo Thomas Schiano Gregory Everson Eugene Schiff Alex Befeler Edward Gane Sammy Saab John G McHutchison G Mani Subramanian William T Symonds Jill Denning Lindsay McNair Sarah Arterburn Evguenia Svarovskaia Dilip Moonka Nezam Afdhal

BACKGROUND & AIMS Patients with detectable hepatitis C virus (HCV) RNA at the time of liver transplantation universally experience recurrent HCV infection. Antiviral treatment before transplantation can prevent HCV recurrence, but existing interferon-based regimens are poorly tolerated and are either ineffective or contraindicated in most patients. We performed a trial to determine whether sofo...

Journal: :Value in health regional issues 2017
Thomas Ward Samantha Webster Sari Mishina Phil McEwan Gail Wygant Feng Wang

BACKGROUND The advent of highly efficacious, well-tolerated, all-oral direct-acting antiviral regimens has revolutionized the standard of care for patients chronically infected with hepatitis C virus. As efficacy and safety rates converge, prescribers and payers need to consider value for money. OBJECTIVES To evaluate the health economic value of daclatasvir + asunaprevir versus sofosbuvir/le...

2016
Robert Flisiak Joanna Pogorzelska Hanna Berak Andrzej Horban Iwona Orłowska Krzysztof Simon Ewelina Tuchendler Grzegorz Madej Anna Piekarska Maciej Jabłkowski Zbigniew Deroń Włodzimierz Mazur Marcin Kaczmarczyk Ewa Janczewska Arkadiusz Pisula Jacek Smykał Krzysztof Nowak Marek Matukiewicz Waldemar Halota Joanna Wernik Katarzyna Sikorska Iwona Mozer-Lisewska Błażej Rozpłochowski Aleksander Garlicki Krzysztof Tomasiewicz Joanna Krzowska-Firych Barbara Baka-Ćwierz Wiesław Kryczka Dorota Zarębska-Michaluk Iwona Olszok Anna Boroń-Kaczmarska Barbara Sobala-Szczygieł Bronisława Szlauer Bogumiła Korcz-Ondrzejek Jerzy Sieklucki Robert Pleśniak Agata Ruszała Barbara Postawa-Kłosińska Jolanta Citko Anna Lachowicz-Wawrzyniak Joanna Musialik Edyta Jezierska Witold Dobracki Beata Dobracka Jan Hałubiec Rafał Krygier Anna Strokowska Wojciech Chomczyk Krystyna Witczak-Malinowska

THE AIM OF THE STUDY Was to analyze the efficacy achieved with regimens available for chronic hepatitis C (CHC) in Poland between 2013 and 2016. MATERIAL AND METHODS Data were collected from 29 centers and included 6786 patients with available sustained virologic response (SVR) data between 1 January 2013 and 31 March 2016. RESULTS The sustained virologic response rate for genotypes (G) 1a,...

2017
S. MADHAVI A. PRAMEELA RANI

Objective: This study points to build up and validate a simple methodology to quantify the most used drug sofosbuvir for the treatment of hepatitis C virus (HCV) infection, in human plasma by using atazanavir as an Internal Standard (IS) for preclinical studies and validate as per USFDA guidelines. Methods: Sofosbuvir was isolated from plasma samples by liquid-liquid extraction method using ace...

Journal: :The Lancet. Global health 2015
Isabelle Andrieux-Meyer Jennifer Cohn Evaldo S Affonso de Araújo Saeed S Hamid

www.thelancet.com/lancetgh Vol 3 November 2015 e676 gross national income (figure). In high-income countries, the price per bottle of sofosbuvir ranged from $14 000 (Spain) to $20 590 (Switzerland). Prices for daclatasvir ranged from $1128 (South Korea) to $14 899 (Germany); those of simeprevir from $9166 (Spain) to $14 865 (Australia); those of ledipasvir-sofosbuvir from $12 604 (USA) to $24 8...

2018
Yuki Haga Tatsuo Kanda Shin Yasui Masato Nakamura Yoshihiko Ooka Koji Takahashi Shuang Wu Shingo Nakamoto Makoto Arai Tetsuhiro Chiba Hitoshi Maruyama Osamu Yokosuka Nobuo Takada Mitsuhiko Moriyama Fumio Imazeki Naoya Kato

Background Interferon-free treatment results in higher sustained virologic response (SVR) rates, with no serious adverse events in hepatitis C virus (HCV)-infected patients. However, in some patients with treatment-failure in HCV NS5A inhibitor-including interferon-free regimens, the treatment-emergent HCV NS5A resistance-associated variants (RAVs), which are resistant to interferon-free retrea...

2014
Evangelos Cholongitas George V. Papatheodoridis

Major changes have emerged during the last few years in the therapy of patients with chronic hepatitis C (CHC). Several direct acting antiviral agents (DAAs) have been developed showing potent activity against hepatitis C virus (HCV) and incrementally improving the rates of sustained virological response (SVR), even in difficult-to-treat CHC patients. Sofosbuvir, a new nucleotide analog, HCV NS...

2017
Zahid Azam Muhammad Shoaib Masood Javed Muhammad Adnan Sarwar Hafeezullah Shaikh Nasir Khokhar

OBJECTIVE The uridine nucleotide analogue sofosbuvir is a selective inhibitor of hepatitis C virus (HCV) NS5B polymerase approved for the treatment of chronic HCV infection with genotypes 1 - 4. The objective of the study was to evaluate the interim results of efficacy and safety of regimens containing Sofosbuvir (Zoval) among Pakistani population with the rapid virologic response (RVR2/4 weeks...

2018

Daily simeprevir (150 mg) plus sofosbuvir (400 mg) 12 weeks I, A Daily daclatasvir (60 mg)b plus sofosbuvir (400 mg) 12 weeks I, B a This is a 3-tablet coformulation. Please refer to the prescribing information. b The dose of daclatasvir may need to be increased or decreased when used concomitantly with cytochrome P450 3A/4 inducers and inhibitors, respectively. Please refer to the prescribing ...

2014
Thomas R. O’Brien Ruth M. Pfeiffer

Treatment of hepatitis C virus (HCV) infection with ledipasvir/sofosbuvir promises tremendous benefits, but high cost may impede implementation of this regimen. Subgroups with excellent response to 8 weeks of treatment might respond to a shorter course. In ION-3, 423 previously untreated HCV genotype 1-infected patients without cirrhosis had outcome data after receiving ledipasvir/sofosbuvir fo...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید